Analyst Anthony Vendetti of Maxim Group maintained a Buy rating on Sensus Healthcare, with a price target of $8.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Anthony Vendetti has given his Buy rating due to a combination of factors that highlight Sensus Healthcare’s potential for growth and financial stability. The company reported third-quarter results that exceeded expectations in terms of revenue, gross margin, and earnings per share, indicating strong operational performance. Additionally, the shipment of 16 Superficial Radiation Therapy systems and an increase in treatment volume under the Fair Deal Agreement demonstrate robust demand for their products.
Another critical factor contributing to the Buy rating is the recent publication of specific CPT codes by the Centers for Medicare and Medicaid Services, which enhances the reimbursement landscape for Sensus’s treatments. This development is expected to drive broader adoption of their technology, as it significantly improves physician economics. Furthermore, Sensus’s strong cash position, with no debt, and strategic initiatives like the Fair Deal program position the company well to capitalize on these favorable market conditions, despite the lowered revenue and earnings estimates for the coming years.
In another report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $6.00 price target.
SRTS’s price has also changed slightly for the past six months – from $4.220 to $4.200, which is a -0.47% drop .